AdvaMed, Patient Groups, State Medtech Associations Urge Medicare Coverage of Breakthrough Medtech 

WASHINGTON, D.C.—AdvaMed, the Medtech Association, is among 67 stakeholder groups, including patient advocacy groups and state medtech and life sciences associations, urging the Centers for Medicare and Medicaid Services (CMS) to create a timely, streamlined pathway for Medicare patients to access FDA-authorized breakthrough medical technology.  

In a letter to CMS Administrator Dr. Mehmet Oz, the 67 organizations noted medtech enables remarkable patient outcomes, yet FDA-designated, authorized breakthrough medtech faces years of delays in Medicare coverage. Continue reading

AZBioPEERS Tales from the Road with Kiran Avancha

In this enlightening conversation with Kiran Avancha, co-founder of priZm Therapeutics, a late-stage clinical biotech company based in Chandler, Arizona shares his journey building a company focused on developing breakthrough therapies for ultra-rare pediatric diseases—including their lead program, SRW101, a novel synthetic T3 molecule for treating AHDS (Allan-Herndon-Dudley Syndrome).Continue reading